This study identifies HMGN2 as a key #Epigenetic regulator in enhancing #Glioma progression by stabilizing #H3K27ac #Acetylation at the CDC20 promoter, positioning the HMGN2/CDC20 axis as a potent target for #GliomaTherapy. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

Rare Diseases Weekly News – April 24th 2025 This Week in Rare Disease Breakthroughs 🧬 | Gene Therapies, Drug Approvals & Global Policy Shifts From a $115M boost […] The post Rare Diseases Weekly News – April 24th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Rare Diseases Weekly News – April 24th 2025 #News #FDA #genetherapy #GliomaTherapy #LGMD Comment below!

Rare Diseases Weekly News – April 24th 2025 This Week in Rare Disease Breakthroughs 🧬 | Gene Therapies, Drug Approvals & Global Policy Shifts From a $115M boost […] The post Rare Diseases Weekly News – April 24th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Rare Diseases Weekly News – April 24th 2025 #News #FDA #genetherapy #GliomaTherapy #LGMD Comment below!

Rare Diseases Weekly News – April 24th 2025 This Week in Rare Disease Breakthroughs 🧬 | Gene Therapies, Drug Approvals & Global Policy Shifts From a $115M boost […] The post Rare Diseases Weekly News – April 24th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Rare Diseases Weekly News – April 24th 2025 #News #FDA #genetherapy #GliomaTherapy #LGMD Comment below!